GLP-1 medicines and asthma
Direct answer
What you need to know
Evidence strength: LimitedSome observational studies associate GLP-1 treatment with fewer asthma exacerbations in people who also have diabetes or obesity. That does not establish a treatment for asthma or a reason to replace an inhaler. The population and comparison group determine what each result can tell you.
Key takeaways
- The studies below observed treatment choices rather than randomly assigning an asthma therapy.
- Diabetes cohorts do not automatically represent everyone with asthma.
- Weight change and other differences may contribute to the association.
- Keep following your prescribed asthma treatment and action plan.
Important limitation: This focused evidence summary is not a systematic review. It does not establish the effectiveness or safety of prescribing a GLP-1 specifically for asthma.
Next action: If you have both asthma and a metabolic condition, ask your clinician how the conditions affect treatment choice; do not assume one medicine will manage both.
Primary sources: Foer and colleagues, 2021, Multinational cohort, 2026, Obesity cohort, September 2026
Three studies, different questions
| Study and population | Finding | Why it is not proof of treatment benefit |
|---|---|---|
| Foer and colleagues, 2021 Adults with asthma and type 2 diabetes starting glucose-lowering medicines. | GLP-1 receptor agonist users had fewer recorded exacerbations than several active comparator groups over six months. | Treatment was not randomly assigned. Baseline differences and clinical prescribing choices can influence the association. |
| Multinational cohort, 2026 Adults with asthma and type 2 diabetes; GLP-1 receptor agonists compared with SGLT-2 inhibitors. | The matched analysis associated GLP-1 treatment with lower risk of a first asthma exacerbation during six-month follow-up. | Electronic health-record data can misclassify exposure or outcomes; matching cannot remove all confounding. |
| Obesity cohort, September 2026 Patients with obesity; GLP-1-based therapy compared with active non-GLP pharmacotherapy. | Fewer recorded respiratory and healthcare-use events over one year were associated with GLP-1-based therapy. | The authors explicitly say residual confounding, uncertain persistence and misclassification prevent causal inference. |
Why researchers are interested
Obesity, diabetes and asthma can coexist. Better metabolic health or weight reduction could affect respiratory outcomes, and researchers are also investigating biological effects of GLP-1 signalling. These explanations need to be distinguished: an association with fewer exacerbations does not tell us how much is attributable to weight change, direct drug effects or other care.
What to discuss at an appointment
- Your established reason for considering a GLP-1, such as weight management or type 2 diabetes.
- Your current asthma control, exacerbations and prescribed action plan.
- All medicines, including corticosteroids, and the monitoring each condition needs.
For the general prescribing decision, start with our GLP-1 treatment guide. For a different respiratory condition with different evidence, see GLP-1 medicines and sleep apnoea.
An asthma attack is not a research question
If breathing is severely difficult or your reliever is not helping, follow your asthma action plan and seek urgent emergency help. Do not wait for a GLP-1 medicine to work.
Frequently asked questions
Do GLP-1 medicines treat asthma?
The observational studies summarised here report associations, not proof that GLP-1 treatment controls asthma. They do not establish a replacement for inhalers or other prescribed asthma treatment.
Does the asthma evidence apply to someone without diabetes?
The earlier studies largely examined people with type 2 diabetes. A newer obesity cohort broadens the population, but still cannot establish that the drug caused better respiratory outcomes. Results should not be generalised to every asthma patient.
Should I stop my inhaler if I start a GLP-1?
No. Do not change prescribed asthma treatment on the basis of these studies. Follow your asthma action plan and discuss any medication changes with your treating clinician.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Foer and colleagues, 2021Primary study abstract indexed in PubMedSupports: Adults with asthma and type 2 diabetes starting glucose-lowering medicines. GLP-1 receptor agonist users had fewer recorded exacerbations than several active comparator groups over six months. Treatment was not randomly assigned. Baseline differences and clinical prescribing choices can influence the association.
- Multinational cohort, 2026Primary study abstract indexed in PubMedSupports: Adults with asthma and type 2 diabetes; GLP-1 receptor agonists compared with SGLT-2 inhibitors. The matched analysis associated GLP-1 treatment with lower risk of a first asthma exacerbation during six-month follow-up. Electronic health-record data can misclassify exposure or outcomes; matching cannot remove all confounding.
- Obesity cohort, September 2026Primary study abstract indexed in PubMedSupports: Patients with obesity; GLP-1-based therapy compared with active non-GLP pharmacotherapy. Fewer recorded respiratory and healthcare-use events over one year were associated with GLP-1-based therapy. The authors explicitly say residual confounding, uncertain persistence and misclassification prevent causal inference.
- Managing asthmaNHLBI, National Institutes of HealthSupports: Follow the asthma action plan, discuss changes with a clinician and recognise when to seek medical attention.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.